Valuation Macro Group Pharmaceuticals (Macro Capital) S.A.E

Stocks

End-of-day quote Egyptian Exchange 29/09/2026			5-day change	1st Jan Change
1.480 ^EGP	+1.37%		-8.64%	+29.82%

05-17	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
05-16	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2025	2026	2027	2028
Market Cap ¹	650	4,995	-	-
Change	-	668.42%	-	-
Enterprise Value (EV) ¹	650	4,915	4,885	4,727
Change	-	656.16%	-0.62%	-3.23%
P/E	5.7x	24.7x	16.4x	13.5x
PBR	-	8.71x	6.73x	5.48x
PEG	-	-0.4x	0.3x	0.6x
Capitalization / Revenue	-	4.2x	3.22x	2.57x
EV / Revenue	-	4.13x	3.15x	2.43x
EV / EBITDA	-	18.1x	12.8x	9.38x
EV / EBIT	-	20.5x	14.5x	10.6x
EV / FCF	-	104x	27.3x	13.7x
FCF Yield	-	0.96%	3.66%	7.32%
Dividend per Share ²	-	0.03	0.04	0.06
Rate of return	-	2.03%	2.7%	4.05%
EPS ²	0.2	0.06	0.09	0.11
Distribution rate	-	50%	44.4%	54.5%
Net sales ¹	-	1,190	1,552	1,946
EBITDA ¹	-	271	381	504
EBIT ¹	-	240	337	444
Net income ¹	115.7	206	283	373
Net Debt ¹	-	-79.7	-110	-268
Reference price ²	1.140	1.480	1.480	1.480
Nbr of stocks (in thousands)	570,206	3,421,239	-	-
Announcement Date	19/02/26	-	-	-

¹EGP in Million²EGP

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
MACRO GROUP PHARMACEUTICALS (MACRO CAPITAL) S.A.E	24.33x	4.13x	18.14x	-	95.87M
ELI LILLY AND COMPANY	33.68x	12.2x	24.79x	0.59%	1,056B
JOHNSON & JOHNSON	30.25x	6.73x	18.83x	1.97%	655B
ABBVIE INC.	33.7x	7.87x	16.27x	2.61%	471B
ROCHE HOLDING AG	19.34x	4.71x	11.68x	2.82%	342B
NOVARTIS AG	20.6x	5.35x	13.29x	2.98%	277B
ASTRAZENECA PLC	21.11x	4.38x	12.46x	2.02%	257B
AMGEN INC.	26.41x	6.87x	12.24x	2.41%	226B
GILEAD SCIENCES, INC.	-46.04x	6.69x	26.14x	2.16%	189B
NOVO NORDISK A/S	11.29x	4.12x	8.55x	4.45%	170B
Average	17.47x	6.31x	16.24x	2.45%	364.3B
Weighted average by Cap.	24.21x	7.89x	18.18x	1.96%